Search clinical trials for: Tyrosine Kinase Inhibitor (TKI)

Total 68699 results

German Cancer Research Center

Completed

Reduction of Cancer Related Fatigue in Patients During TKI Therapy (RECAP)

All Tumor Entities Treated With TKI Therapy

Germany
Spanish Lung Cancer Group

Completed

T790M Mutation Testing in Blood by Different Methodologies

NSCLC Stage IV

Spain
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

CML, CML-CP,MMR,TKI

China
xuna

Recruiting

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

MMR on 12 Month

China
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
Tongji Hospital
Wuhan University; Hubei Cancer Hospital; Wuhan Union Hospital, China; Renmin Hospital...

Completed

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Withdrawal or Reduction TKIs in CML-CP

MMR on 12 Month

China
Neurological Associates of West Los Angeles
Pfizer

Enrolling by invitation

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Dementia | Mild Cognitive Impairment

United States
Zhejiang University

Unknown

Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression

Non Small Cell Lung Cancer

China
Pfizer

Completed

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Renal Cell Carcinoma (RCC)

United States
xuna
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaborators

Withdrawn

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT (Case-Only)

Prophylactic HQP1351 Therapy | Third Generation TKI

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
University Health Network, Toronto

Unknown

Allogeneic SCT for CML, TKI Failure After TKI Failure

Chronic Myeloid Leukemia

Canada
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Northwestern University

Completed

Oncotool for Cancer Medications

Cancer | Communication | Medication Adherence | Cancer, Treatment-Related | Tyrosine Kinase Inhibitor

United States
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Nanfang Hospital of Southern Medical University
Guangxi Medical University; Peking University People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

China
Poitiers University Hospital

Recruiting

Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

Chronic Myeloid Leukemia | Tyrosine Kinase Inhibitors

France
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study

Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Medical College of Wisconsin

Not yet recruiting

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Non Small Cell Lung Cancer

United States
Telios Pharma, Inc.

Completed

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

COVID-19 | Carcinoma | Cancer | Solid Tumor | Sars-CoV2 | Blood Cancer

United States
Fuda Cancer Hospital, Guangzhou

Completed

Cryotherapy Combine Icotinib for Advanced NSCLC Treatment

Lung Neoplasms
Yuankai Shi

Unknown

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Novartis Pharmaceuticals

Completed

Study Conducted Among Patients With CML

Chronic Myeloid Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation; H. Jean Khoury Cure CML Consortium

Recruiting

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid Leukemia

United States
Fujian Cancer Hospital

Recruiting

HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Thyroid Cancer | Health Related Quality of Life | Tyrosine Kinase Inhibitor

China
Lady Davis Institute
Jewish General Hospital

Unknown

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

Lung Cancer

Canada
Centre Oscar Lambret

Completed

Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI-CPK-1003)

Cancer | Solid Tumor

France
The First Affiliated Hospital of Soochow University

Completed

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Philadelphia Chromosome | Mixed Phenotype Acute Leukemia

China
University of Salerno

Unknown

Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors

Differentiated Thyroid Cancer

Italy
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | Tyrosine Kinase Inhibitor

China
Bayer

Completed

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib (ROCURS)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection | Malignant Solid Tumors

United States
Xinjiang Medical University

Unknown

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Non-Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer
Zaiwen Fan

Unknown

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Advanced Cancer | Lung Cancer, Nonsmall Cell
Assiut University

Active, not recruiting

Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Patients Diagnosed as Chronic Meyloid Leukemia

Egypt
Catholic University of the Sacred Heart

Completed

Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors

Renal Cell Cancer | Diarrhea Caused by Drug (Disorder)

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Pusan National University Hospital
Yuhan Corporation

Not yet recruiting

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Non-small Cell Lung Cancer

Korea, Republic of
Erasmus Medical Center

Recruiting

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI) (START-TKI)

Non Small Cell Lung Cancer | Liquid Biopsy | Tyrosine Kinase Inhibitor

Netherlands
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Li Zhang, MD

Recruiting

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance (ERSGATR)

The Diagnosis Was ALK Positive NSCLC | Second Generation ALK-TKI is Resistant | Efficacy of Ensatinib in This Subset of Patients

China
Tata Memorial Hospital

Recruiting

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC (TARGET-01)

Non-small Cell Lung Cancer | Oligometastatic Disease | Driver Mutation

India
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Renal Cell Carcinoma
Nanfang Hospital of Southern Medical University

Recruiting

Cancer-associated Gene Mutations in CML Treatment With TKIs by NGS

Different Gene Between Different TKIs Effection

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China

Search clinical trials for: Tyrosine Kinase Inhibitor (TKI)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations